Shares of Evotec SE (NASDAQ:EVO - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $3.78, but opened at $3.96. Evotec shares last traded at $3.92, with a volume of 21,718 shares changing hands.
Analysts Set New Price Targets
Several brokerages recently commented on EVO. Royal Bank of Canada reissued an "outperform" rating on shares of Evotec in a research note on Thursday, May 15th. Deutsche Bank Aktiengesellschaft raised Evotec from a "sell" rating to a "hold" rating in a report on Thursday, April 24th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, Evotec currently has a consensus rating of "Hold" and an average price target of $5.93.
Get Our Latest Research Report on EVO
Evotec Trading Up 0.3%
The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43. The business has a fifty day simple moving average of $3.78 and a two-hundred day simple moving average of $4.16.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. DCF Advisers LLC boosted its holdings in shares of Evotec by 227.0% during the 1st quarter. DCF Advisers LLC now owns 751,579 shares of the company's stock valued at $2,510,000 after acquiring an additional 521,708 shares during the last quarter. ABC Arbitrage SA purchased a new position in Evotec during the first quarter valued at $260,000. Lighthouse Investment Partners LLC bought a new position in shares of Evotec in the fourth quarter worth about $166,000. CSS LLC IL purchased a new position in Evotec during the fourth quarter valued at approximately $50,000. Finally, Bank of America Corp DE lifted its stake in shares of Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after buying an additional 9,289 shares in the last quarter. Institutional investors own 5.81% of the company's stock.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Featured Stories
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
